PURPOSE: We identified genetic predictors of diabetes associated erectile dysfunction using genome-wide and candidate gene approaches in a cohort of men with type 1 diabetes. MATERIALS AND METHODS: We examined 528 white men with type 1 diabetes, including 125 with erectile dysfunction, from DCCT (Diabetes Control and Complications Trial) and its observational followup, the EDIC (Epidemiology of Diabetes Interventions and Complications) study. Erectile dysfunction was identified from a single International Index of Erectile Function item. A Human1M BeadChip (Illumina®) was used for genotyping. A total of 867,125 single nucleotide polymorphisms were subjected to analysis. Whole genome and candidate gene approaches were used to test the hypothesis that genetic polymorphisms may predispose men with type 1 diabetes to erectile dysfunction. Univariate and multivariate models were used, controlling for age, HbA1c, diabetes duration and prior randomization to intensive or conventional insulin therapy during DCCT. A stratified false discovery rate was used to perform the candidate gene approach. RESULTS: Two single nucleotide polymorphisms located on chromosome 3 in 1 genomic loci were associated with erectile dysfunction with p <1 × 10(-6), including rs9810233 with p = 7 × 10(-7) and rs1920201 with p = 9 ×10(-7). The nearest gene to these 2 single nucleotide polymorphisms is ALCAM. Genetic association results at these loci were similar on univariate and multivariate analysis. No candidate genes met the criteria for statistical significance. CONCLUSIONS: Two single nucleotide polymorphisms, rs9810233 and rs1920101, which are 25 kb apart, are associated with erectile dysfunction, although they do not meet the standard genome-wide association study significance criterion of p <5 × 10(-8). Other studies with larger sample sizes are required to determine whether ALCAM represents a novel gene in the pathogenesis of diabetes associated erectile dysfunction.
RCT Entities:
PURPOSE: We identified genetic predictors of diabetes associated erectile dysfunction using genome-wide and candidate gene approaches in a cohort of men with type 1 diabetes. MATERIALS AND METHODS: We examined 528 white men with type 1 diabetes, including 125 with erectile dysfunction, from DCCT (Diabetes Control and Complications Trial) and its observational followup, the EDIC (Epidemiology of Diabetes Interventions and Complications) study. Erectile dysfunction was identified from a single International Index of Erectile Function item. A Human1M BeadChip (Illumina®) was used for genotyping. A total of 867,125 single nucleotide polymorphisms were subjected to analysis. Whole genome and candidate gene approaches were used to test the hypothesis that genetic polymorphisms may predispose men with type 1 diabetes to erectile dysfunction. Univariate and multivariate models were used, controlling for age, HbA1c, diabetes duration and prior randomization to intensive or conventional insulin therapy during DCCT. A stratified false discovery rate was used to perform the candidate gene approach. RESULTS: Two single nucleotide polymorphisms located on chromosome 3 in 1 genomic loci were associated with erectile dysfunction with p <1 × 10(-6), including rs9810233 with p = 7 × 10(-7) and rs1920201 with p = 9 ×10(-7). The nearest gene to these 2 single nucleotide polymorphisms is ALCAM. Genetic association results at these loci were similar on univariate and multivariate analysis. No candidate genes met the criteria for statistical significance. CONCLUSIONS: Two single nucleotide polymorphisms, rs9810233 and rs1920101, which are 25 kb apart, are associated with erectile dysfunction, although they do not meet the standard genome-wide association study significance criterion of p <5 × 10(-8). Other studies with larger sample sizes are required to determine whether ALCAM represents a novel gene in the pathogenesis of diabetes associated erectile dysfunction.
Authors: Mary E Fischer; Mary Ellen Vitek; Don Hedeker; William G Henderson; Steven J Jacobsen; Jack Goldberg Journal: Arch Intern Med Date: 2004-01-26
Authors: Hunter Wessells; David F Penson; Patricia Cleary; Brandy N Rutledge; John M Lachin; Kevin T McVary; David S Schade; Aruna V Sarma Journal: J Urol Date: 2011-03-21 Impact factor: 7.450
Authors: F B Brotons; J C Campos; R Gonzalez-Correales; A Martín-Morales; I Moncada; J M Pomerol Journal: Int J Impot Res Date: 2004-10 Impact factor: 2.896
Authors: Kevin G Becker; Douglas A Hosack; Glynn Dennis; Richard A Lempicki; Tiffani J Bright; Chris Cheadle; Jim Engel Journal: BMC Bioinformatics Date: 2003-12-10 Impact factor: 3.169
Authors: M Maciukiewicz; V S Marshe; A K Tiwari; T M Fonseka; N Freeman; J L Kennedy; S Rotzinger; J A Foster; S H Kennedy; D J Müller Journal: Pharmacogenomics J Date: 2017-07-11 Impact factor: 3.550
Authors: Darshan P Patel; Jeannette M Schenk; Amy Darke; Jeremy B Myers; William O Brant; James M Hotaling Journal: BJU Int Date: 2015-09-20 Impact factor: 5.588
Authors: David M Nathan; Margaret Bayless; Patricia Cleary; Saul Genuth; Rose Gubitosi-Klug; John M Lachin; Gayle Lorenzi; Bernard Zinman Journal: Diabetes Date: 2013-12 Impact factor: 9.461